Chemotherapy Controlled Substances FDA 
The FDA Law Blog
JANUARY 18, 2024
Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. By Larry K. 53,688 (Aug. 53,767 (Aug. 21 U.S.C. §
The Checkup by Singlecare
MARCH 23, 2023
The United States Congress legalized CBD derived from hemp in 2018 when the Agricultural Improvement Act was signed into law, removing hemp from the Federal Controlled Substances Act. However, at the federal level, marijuana is still classified as a Schedule I controlled substance by the Drug Enforcement Agency (DEA).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Checkup by Singlecare
MAY 8, 2023
Tramadol has been available in the United States since 1995, but not until 2014 did it become a schedule IV controlled substance by the Food and Drug Administration (FDA) based on data suggesting abuse potential similar to other schedule IV opioids available at that time. What can I take in place of tramadol?
The Checkup by Singlecare
MARCH 21, 2023
Today, it is approved by the Food and Drug Administration ( FDA ) for chronic musculoskeletal pain—like low back pain , neuropathic pain associated with diabetes mellitus , and fibromyalgia; it is used off-label for chemotherapy-induced peripheral neuropathy.
The FDA Law Blog
MAY 21, 2024
Houck — Last August Health and Human Services (“HHS”) recommended rescheduling marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. Schedules of Controlled Substances: Rescheduling of Marijuana, 89 Fed. By Larry K. 44,597 (May 21, 2024). 29, 2023) (“Basis”); NPRM at 44,603.
The FDA Law Blog
MAY 5, 2024
Houck — The Associated Press reported on Tuesday following confirmation by five anonymous individuals with knowledge that the Drug Enforcement Administration (“DEA”) is moving to reschedule marijuana from schedule I to the less stringently controlled schedule III. Whether the drug is an immediate precursor of a substance already controlled.
The FDA Law Blog
FEBRUARY 11, 2024
FDA has not approved marijuana for medical use because no double-blind, published studies show safety and efficacy for raw marijuana. In other words, no rescheduling. There has been no evidence that marijuana’s schedule should change since the last rescheduling review in 2016.
Expert insights. Personalized for you.
69 
Let's personalize your content